Hypothetical Concerns

It was refreshing to read the comments of David Horrobin in "Discouraging Hypotheses Slows Progress." I have thought about this problem many times and feel that a journal--perhaps called Idea--might help. An article considered for publication would not be peer reviewed and would have to meet only the following criteria: Is it written in readable English? Is it free of nonscience motives? Is it free of perpetual motion machines? Is it new? Everything should be left to the reader. Most peculiarl

Written byChristian Schwabe
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Everything should be left to the reader. Most peculiarly, many of those who may agree publicly with the views expressed in Horrobin's article will be quick to dismiss papers of opposing views that they review alone and anonymously in their office. These are the basic characteristics of man, I fear--a mixture of jealousy and conceit: "If the idea were any good, I would have had it earlier." Refereeing new ideas impartially is simply not possible. Conversely, there are readers who have open minds--because they are not specialists in a particular field--and who would read with interest. Even if everything written will not end up chiseled in stone, wrong ideas have a habit of sparking correct ones in somebody s mind.

Censorship of ideas is the most destructive byproduct of the legitimate review activity in the experimental sciences; the journal created by Horrobin is certainly a step in the right direction.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies